These findings identify FBXO9 as a tumor suppressor via its facilitation of PD-L1 degradation, underscoring the potential of targeting FBXO9 in immunotherapeutic approaches for treating cancers, particularly in combination with anti-PD-L1 therapy. This evidence concerns the gene CD274 and neoplasm.